IMP-1 inhibits renal cell carcinoma 786-O cell growth by targeting EphrinB2 signaling pathway. Brazilian Journal of Pharmaceutical Sciences, [S. l.], v. 59, p. e22102, 2023. DOI: 10.1590/s2175-97902023e22102 . Disponível em: https://journals.usp.br/bjps/article/view/213468.. Acesso em: 9 apr. 2025.